임상 한눈에 보기

• 3건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• Phase: Phase 4 · Phase 3
• Status: Completed
• 주요 endpoint: Percentage of Subjects Who Met the American College of Rheumatology 20 % (ACR20) Criteria at Week 12 · Percentage of Subjects Who Had a Disease Activity Score 28 [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) ≤ 3.2 at Week 104 · Response at Week 12 as Assessed by Randomized Tool [Clinical Disease Activity Index (CDAI) or Routine Assessment of Patient Index Data 3 (RAPID3)] · Responders at Week 12 (as Assessed by Randomized Tool Clinical Disease Activity Index [CDAI] or Routine Assessment of Patient Index Data [RAPID3]) Achieving Low Disease Activity (Disease Activity Score 28 [Erythrocyte Sedimentation Rate]≤3.2) at Week 52 · Percent Change From Baseline in Synovial TNFa
• 등록 대상자(표본 합산): 약 1,663명

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.